Could a common supplement tame multiple sclerosis?
NCT ID NCT07263607
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding taurine, a natural amino acid, to standard multiple sclerosis (MS) medications can improve outcomes. About 80 adults with relapsing-remitting MS will either continue their usual drugs or add daily taurine for 24 months. Researchers will track brain lesions, relapses, disability, and gut health to see if taurine offers extra protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
taurine
What this could lead to
If it works, adding taurine to standard MS therapy could help reduce brain damage, relapses, and slow disability progression.
What could go wrong
This is a small, early-phase trial with only 80 people. Taurine may show no added benefit over standard drugs, and results may not apply to all MS patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••